We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




European Remote Patient Monitoring Market

By HospiMedica staff writers
Posted on 15 Jul 2008
Innovation and advanced technology continue to play a significant role in the remote patient monitoring (RPM) market, making available devices increasingly attractive. More...
These are the latest findings from Frost & Sullivan (Frost, Palo Alto, CA, USA), an international consulting firm.

However, while technology is constantly changing to support better healthcare services, steadily improving patient monitoring capabilities, the limited reimbursement offered by European governments is dampening market potential. The lack of adequate reimbursement streams will pose a major challenge to companies wishing to boost their unit sales and market revenues. Privacy and confidentiality issues are further clouding the market.

"A critical challenge is governments' refusal to reimburse remote monitoring of patients,” said Frost & Sullivan research analyst Janani Narasimhan. "With no financial incentive for healthcare providers to implement this technology, providers are likely to view RPM as an increase in workload without a subsequent hike in pay. On the other hand, connecting personal health information to the Internet exposes this data to more hostile attacks than paper-based medical records.”

"The heightened demands of an aging population and a related increase in chronic diseases are encouraging market growth,” added Ms. Narasimhan. "RPM has the potential to change the way patients manage their own conditions so that they become the keepers of their own healthcare.”

Frost and Sullivan has found that the European RPM market earned revenues of U.S. $175 million in 2007 and estimates this to reach $400 million by 2014.


Related Links:
Frost & Sullivan

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.